Treatment of chronic graft-versus-host disease with human umbilical cord mesenchymal stem cells

doi:10.3969/j.issn.2095-4344.2014.50.010

Abstract

Abstract:

BACKGROUND: Mesenchymal stem cells have immunomodulatory effects, which have been proven to be successful in treating acute graft-versus-host disease. However, there are fewer reports concerning human umbilical cord mesenchymal stem cells in treating chronic graft-versus-host disease, particularly for lung-type chronic graft-versus-host disease.
OBJECTIVE: To evaluate the effect of human umbilical cord mesenchymal stem cells to treat chronic graft-versus-host disease after hematopoietic stem cell transplantation.
METHODS: Ten patients undergoing allo-hematopoietic stem cell treatment were clearly diagnosed as having chronic graft-versus-host disease, and had no improvement after conventional immunosuppressive therapy. These patients received the treatment of human umbilical cord mesenchymal stem cells, 2×107 cells per curative unit, 1-2 units every two weeks. The therapeutic results were evaluated according to the clinical standards.
RESULTS AND CONCLUSION: In four patients with lung-type chronic graft-versus-host disease, three patients were effective. In two patients with skin-type chronic graft-versus-host disease, one patient had progress, and another one was effective. In four patients of liver rejection, two patients were effective and the other two were ineffective. The total effective rate was 70% (7/10). Human umbilical cord mesenchymal stem cell infusion can be effective to refractory chronic graft-versus-host disease.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: umbilical cord, mesenchymal stem cell transplantation, graft vs host disease

CLC Number:

R394.2

Huang Ying-dan, Xiao Cui-rong, Lin Jin-zong, Hong Xiu-li, Hu Jia-sheng, Lu Quan-yi. Treatment of chronic graft-versus-host disease with human umbilical cord mesenchymal stem cells[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(50): 8093-8097.

Figures/Tables 1

References

[1] Dreger P, Schmitz N.Allogeneic transplantation of blood stem cells: coming of age.Ann Hematol. 2001;80(3):127-136.
[2] Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial.Lancet. 2000; 355 (9211):1231-1237.
[3] Shlomchik WD.Antigen presentation in graft-vs-host disease.Exp Hematol. 2003;31(12):1187-1197.
[4] Sarantopoulos S, Stevenson KE, Kim HT,et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.Clin Cancer Res. 2007;13(20): 6107-6114.
[5] Sullivan KM, Shulman HM, Storb R,et al.Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.Blood. 1981;57(2):267-276.
[6] Ferrara JL, Levine JE, Reddy P, et al.Graft-versus-host disease.Lancet. 2009;373(9674):1550-1561.
[7] Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.Transplantation. 2006;81(10):1390-1397.
[8] Lazarus HM, Koc ON, Devine SM,et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.Biol Blood Marrow Transplant. 2005;11(5):389-398.
[9] Le Blanc K, Rasmusson I, Sundberg B,et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.Lancet. 2004; 363 (9419):1439-1441.
[10] 陈广华,杨婷,田竤,等.脐带间充质干细胞治疗糖皮质激素耐药的严重型急性移植物抗宿主病19例分析[J].中华血液学杂志,2012, 33(4): 303-306.
[11] 乔淑敏,陈广华,王易,等.脐带间充质干细胞治疗儿童异基因造血干细胞移植后急性移植物抗宿主病疗效观察[J].中国实验血液学杂志,2013,21(3):716-720.
[12] 张乐施,刘启发,黄科.间充质干细胞治疗糖皮质激素耐药性慢性移植物抗宿主病临床疗效观察[J].中华内科杂志,2009,48(7): 542-546.
[13] Aggarwal S, Pittenger MF.Human mesenchymal stem cells modulate allogeneic immune cell responses.Blood. 2005; 105(4):1815-1822.
[14] 周虹,郭梅,孙琪云,等. 骨髓间充质干细胞移植治疗硬皮病样慢性移植物抗宿主病:4例免疫机制变化[J].中国组织工程研究与临床康复,2010,14(10):1885-1891.
[15] 吕璐璐,刘拥军,许贞书,等.脐带源间充质干细胞的分离和生物学性状[J].福建医科大学学报,2006,40(2):99-104.
[16] 牛小青,鹿全意,王昭,等.含氟达拉滨的预处理行异基因造血干细胞移植治疗恶性血液病的远期疗效[J].中国肿瘤临床,2009, 36(1): 25-29.
[17] Gronthos S, Franklin DM, Leddy HA,et al. Surface protein characterization of human adipose tissue-derived stromal cells.J Cell Physiol. 2001;189(1):54-63.
[18] Campagnoli C, Roberts IA, Kumar S,et al.Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow.Blood. 2001;98(8): 2396-2402.
[19] Igura K, Zhang X, Takahashi K,et al. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta.Cytotherapy. 2004;6(6): 543-553.
[20] Ball LM, Bernardo ME, Roelofs H,et al.Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood. 2007;110(7):2764-277.
[21] Le Blanc K, Frassoni F, Ball L,et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.Lancet. 2008; 371(9624):1579-1586.
[22] Li JJ, Li D, Ju XL, et al. Umbilical cord-derived mesenchymal stem cells retain immunomodulatory and anti-oxidative activities after neural induction. Neural Regen Res.2012; 7(34): 2663-2672.
[23] Zhou J, Tian GP, Wang J, et al. Neural cell injury microenvironment induces neural differentiation of human umbilical cord mesenchymal stem cells. Neural Regen Res. 2012; 7(34): 2689-2697.
[24] Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.Transplantation. 2006;81(10):1390-1397.
[25] Xu G, Zhang L, Ren G,et al. Immunosuppressive properties of cloned bone marrow mesenchymal stem cells.Cell Res. 2007; 17(3):240-248.
[26] Ivanova-Todorova E, Bochev I, Dimitrov R,et al. Conditioned medium from adipose tissue-derived mesenchymal stem cells induces CD4+FOXP3+ cells and increases IL-10 secretion.J Biomed Biotechnol. 2012;2012:295167.
[27] Krampera M, Glennie S, Dyson J,et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101(9):3722-3729.
[28] 陆英,张祥忠,刘相富,等.间充质干细胞输注对于移植物抗宿主病中不同受损器官的治疗效果[J].中国组织工程研究,2014,18(23): 3676-3681.
[29] Soubani AO, Uberti JP.Bronchiolitis obliterans following haematopoietic stem cell transplantation.Eur Respir J. 2007 May;29(5):1007-1019.
[30] Bergeron A, Godet C, Chevret S,et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis.Bone Marrow Transplant. 2013;48(6):819-824.
[31] Ning H, Yang F, Jiang M,et al.The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study.Leukemia. 2008;22(3):593-599.
[32] 刘晓丹,范志平,彭延文,等. 第三方骨髓间充质干细胞治疗异基因造血干细胞移植后继发性植入功能不良的疗效及安全性[J].中华血液学杂志,2012,33(2):98-102.
[33] 宋丽,陈嘉林.间充质干细胞免疫调节作用及其在自身免疫病中的意义[J].基础医学与临床, 2009,29(11):1221-1223.